Thyroid Cancer: health plans must include new treatment with Lenvatinib Mesylate (Lenvima).

The National Supplementary Health Agency (ANS) recently announced an important update to its List of Procedures and Events in Health, which defines the mandatory healthcare coverage for health plans.

The highlight of this update is the inclusion of lenvatinib mesylate treatment for thyroid cancer.

This decision, announced on May 31, brings hope to patients facing this disease and whose conventional treatment options, such as surgery and radiotherapy, have not been effective.

Lenvatinib mesylate: the new therapeutic option for thyroid cancer

Thyroid cancer is a serious condition that affects the thyroid gland, which is responsible for producing hormones that are important for the body's metabolism.

THE lenvatinib mesylate It is a medicine that has demonstrated efficacy by inhibiting the growth of blood vessels that feed tumors, thus preventing the progression of the disease.

Its inclusion in the ANS list means that health plans will be required to cover this treatment from July 3rd, provided there is adequate medical indication.

The coverage of the lenvatinib mesylate will be provided to thyroid cancer patients who have failed conventional surgery and radiotherapy, providing an additional therapeutic option.

Lenvatinib mesylate shows promise as a treatment option for advanced or metastatic thyroid cancer, providing new hope for those facing this disease.

More access to treatment

ANS emphasizes that the inclusion of new technologies in its list is a victory for both beneficiaries and the sustainability of the sector. After all, ensuring access to innovative and effective treatments is essential to improving patients' quality of life and offering more advanced therapeutic options.

The inclusion of this medication in the list of mandatory procedures for health plans is an important milestone, as it expands patients' access to treatment, reducing bureaucracy and financial obstacles.

The National Federation of Supplementary Health (Fenasúde), an entity that represents health plan operators, chose not to comment on the inclusion of lenvatinib mesylate in the ANS list.

A joint fight against thyroid cancer

The fight against thyroid cancer requires a multidisciplinary approach, involving doctors, patients, family members and health plan operators.

It is essential that physicians and patients are aware of this new option and that health plans comply with their obligation to cover lenvatinib mesylate, ensuring equal access to this therapy.

Starting July 3, patients will have mandatory coverage of this medication by health plans, allowing them to face thyroid cancer with more therapeutic resources.

For more news, visit our website I am healthy, follow on Instagram @tenhosaude and on TikTok @tenhosaude.com.

Source: National Supplementary Health Agency (ANS) and Brazil Agency.